Rigel Investor & Analyst Day
Rigel’s management team will discuss the launch of Tavalisse™ including the achievements to date and ongoing efforts of the commercial team. Dr. Amit Mehta will provide a community physician’s perspectives on clinical use of Tavalisse and how this therapy fits within the current treatment paradigm for immune thrombocytopenia (ITP).
In addition, the presentation will provide an update on plans for the company’s pivotal program in autoimmune hemolytic anemia (AIHA) and overview further pipeline opportunities Rigel is pursuing. The team will be joined by Dr. David J. Kuter, who will offer insights on the investigational study of fostamatinib in AIHA, a rare disease that lacks sufficient treatment options.
Additional business updates will also be discussed.
Thursday, October 4, 2018
Registration & Lunch
12:00 PM to 2:30 PM
Maxwell Hotel (formerly the W Hotel)
541 Lexington Avenue, New York, NY
Amit Mehta, MD, Board-certified Hematologist/Medical Oncologist, Premier Hematology, Cary, N.C., Affiliated with Duke University
Dr. Mehta received his MD from the Rutgers – Robert Wood Johnson Medical School and completed his undergraduate studies in bioengineering at the University of Pennsylvania. He completed his fellowship in hematology & oncology at the Rutgers Cancer Institute of New Jersey.
Dr. Mehta was previously on faculty at Duke University Medical Center and is currently in private practice at Premier Hematology in Cary, NC. He maintains a hospital affiliation with Duke University Hospital. His primary interests and research focus are in benign and malignant hematology, and he has extensive clinical experience with complex clotting and bleeding disorders. He has multiple publications in these areas as well.
While at the University of Pennsylvania, Dr. Mehta was engaged in laboratory research in the Syk pathway in cell models and mice, the key pathway inhibited by Tavalisse (fostamatinib). He has also given multiple Grand Rounds and CME lectures, and presented at national conferences including The American Society of Clinical Oncology (ASCO).
David J. Kuter, MD, DPhil, Director, Clinical Hematology, Massachusetts General Hospital, Professor, Medicine, Harvard Medical School
Dr. Kuter received his undergraduate degree from Harvard College and his D. Phil. in Biochemistry while a Rhodes Scholar at Oxford University. He currently divides his time between medical education of fellows and medical students, clinical care of patients with a wide range of hematological disorders, and clinical research of thrombopoietic agents.
Dr. Kuter’s basic science group was one of the labs that discovered thrombopoietin and his clinical research group carried out seminal studies using thrombopoietic agents in transfusion medicine and immune thrombocytopenia (ITP). Dr Kuter is recipient of a number of awards for his research in hematology and teaching. He has given over 500 invited lectures in over 50 countries and served as Visiting Professor in Beijing, Sydney, Tokyo, London, Durham, and New Haven.
He has authored or co-authored over 300 articles published in international peer-reviewed journals such as The Lancet, The New England Journal of Medicine and Blood.
- Raul R. Rodriguez, President and Chief Executive Officer
- Eldon C. Mayer, Chief Commercial Officer
- Anne-Marie Duliege, MD, Chief Medical Officer
- Esteban Masuda, PhD, Sr. Vice President, Research
- Dean Schorno, Chief Financial Officer
Director, Investor Relations and Communications
Rigel Pharmaceuticals, Inc.